Both of the aforementioned studies suggest that TYMS may be a suitable marker of sensitivity to pemetrexed-based chemotherapy in patients with NSCLC, although one of them indicates that the prognostic value of TYMS protein expression may need further validation. This evidence concerns the gene TYMS and non-small cell lung carcinoma.